Making money while fighting the good fight.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I see .01 in the future. Yikes.
GLTA & JMO
I'm back! And you know that means unfortunately.
It means that HALO has fallen into the .02 range.
Hate to say it but I told you so.
Soon sub-penny with a reverse split cometh.
GLTA & JMO
Xebec Hires Senior Executives to Support Next Phase of Growth
10/13/2020 8:00:00 AM
Two executive hires for legal and industrial leadership
MONTREAL, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Xebec Adsorption Inc. (TSXV: XBC) (“Xebec”), a global provider of clean energy solutions, is pleased to announce today two key management hires.
Nathalie Théberge is Xebec’s first Vice President, Legal Affairs & Corporate Secretary. Ms. Théberge is a seasoned corporate lawyer with solid experience in the renewable energy industry. She was most recently at Innergex Renewable Energy, where she spent close to a decade overseeing matters related to securities, corporate law, governance, acquisitions, strategic joint ventures and business financing. Ms. Théberge brings over 25 years of legal experience with her time at Lacoste Langevin, Bombardier Capital, Cascades and Innergex.
Russell Warner is joining the team as Xebec’s first Vice President, Industrial and will be leading the company’s Cleantech Service Network expansion strategy for renewable natural gas and hydrogen installations. Based out of Charlotte, North Carolina, Mr. Warner has proven his ability to be a large-scale product leader within the compressed air industry as an executive at Sullair and Doosan Infracore Portable Power (formerly Ingersoll Rand Utility Equipment). Throughout his career, he has been responsible for launching new products and services that gained significant market share, established 10-year product roadmaps and brought several teams towards profitable growth and increased customer satisfaction.
“It is my pleasure to welcome Nathalie and Russell to the Xebec team. These hires are some of the most senior we have made to date and are critical to our continued expansion and creating a world leading renewable gas company. Organizational development is a key focus of mine as we need to have the right people lead our further growth. I’m happy with the level of expertise each one of them brings in their respective field and look forward to their contributions in the coming years,” states Kurt Sorschak, Chairman, CEO and President of Xebec.
Related links:
www.xebecinc.com
For more information:
Xebec Adsorption Inc.
Brandon Chow, Investor Relations Manager
bchow@xebecinc.com
+1 450.979.8700 ext 5762
About Xebec Adsorption Inc.
Xebec is a global provider of gas generation, purification and filtration solutions for the industrial, energy and renewables marketplace. Well-positioned in the energy transition space with proprietary technologies that transform raw gases into clean sources of renewable energy, Xebec’s 1500+ customers range from small to multi-national corporations, governments and municipalities looking to reduce their carbon footprints. Headquartered in Montréal, Quebec, Canada, Xebec has several Sales and Support offices in North America and Europe, as well as two manufacturing facilities in Montréal and Shanghai. Xebec trades on the TSX Venture Exchange under the symbol XBC. For more information, www.xebecinc.com.
LOL.
I sense sarcasm or vengeance.
Both of which are not great virtues when investing.
GLTA & JMO
You got that right.
lots of catalysts and upside on deck.
GLTA & JMO
Instead of litigating the sentiment of the post I will only commit to returning once this hits .02
Then we can discuss the "a trade's a trade" mentality.
AND I do agree with you on this point:
As a notorious crook recently said, "it is what it is."
GLTA & JMO
Thats what they said at .50, .40, .30, .20, .10, etc.
See the pattern?
A good buying opportunity for capital losses.
I mean really.
GLTA & JMO
Its not what I say.. they ARE sells according to how they market records those trades.
1M shares traded today so far and the price is moving in the wrong direction.
GLTA & JMO
Almost all trades were sold into the BID today.
Not a great sign.
GLTA & JMO
Like I said.. get ready for another double black diamond slope.
The lower the PPS the more toxic the financing and dilution becomes.
GLTA & JMO
TD Initiates Analyst Coverage with 12-month $6.50 PT
Xebec Adsorption Inc. (XBC-V) C$4.18 Profitable Today, Powering Tomorrow; Initiating at BUY
Event
We are initiating coverage on Xebec Adsorbtion Inc. with a BUY rating and $6.50 target price.
Note: A more detailed report will be published later today
.02 or less.
Without an RS.
Nothing goes up or down in a straight line. And the downward pressure will return after the Q.
GLTA & JMO
BINGO.
Wash, rinse, repeat.
GLTA & JMO
Really? You want to average down?
Is that a good idea?
I mean really. Wait for the .02s maybe..
Spigots of dilution are wide wide open.
I cant even make this stuff up.
GLTA & JMO
Careful what you wish for.
LOL
Another penny stock that will end up in the pinksheet graveyard.
GLTA & JMO
Its a pattern. You get used to seeing it with experience.
Its nothing to be proud of but I hope it helps others long term.
The more things change the more they stay the same.
GLTA & JMO
Are you nuts?
This is going to .02 ahead of an R/S.
I mean how many times do I have to point to the wall.
GLTA & JMO
Where have I heard that before?
;)
GLTA & JMO
I'll take that bet..
GLTA & JMO
Xebec Expands Cleantech Service Network with Acquisition of British Columbia Based Applied Compression Systems
Fourth acquisition in Xebec’s strategy to develop a North American service footprint for renewable natural gas and hydrogen installations
MONTREAL, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Xebec Adsorption Inc. (TSXV: XBC) (“Xebec”), a global provider of clean energy solutions is pleased to announce that the Company has entered into an agreement effective August 31st, 2020, to acquire all of the outstanding securities of Applied Compression Systems Ltd. (“ACS”). ACS’ principals will remain with ACS after the acquisition to optimize their integration into Xebec’s industrial service and support business and to grow the operation over the coming years.
Xebec’s Cleantech service coverage will increase and now include British Columbia, a province with the country’s most aggressive renewable natural gas and hydrogen mandates and targets. ACS has existing experience and customer relationships for servicing renewable gas installations.
Total consideration payable by Xebec is approximately $4.5M, subject to certain holdbacks, adjustments and time-based payments. ACS had revenues of over $8.0 million for the last twelve months with an EBITDA margin of approximately 12%. As with other acquisitions in the Industrial Service and Support segment, Xebec expects that ACS’ growth and profitability could be improved with sourcing and back-office synergies.
When customers select a vendor for a multi-million-dollar renewable natural gas or hydrogen installation, service and support figures prominently in their purchasing decision. With its service acquisition strategy Xebec responds to this important customer need and sees it as competitive advantage due to the lack of a similar offering from other vendors. Furthermore, the expansion of its Cleantech Service Network (“CSN”), is set to expand across North America over the coming years. In addition, this strategy will lead to increased recurring aftermarket sales with a positive impact on overall profitability. As a result, Xebec expects revenues of approximately $200 million in its Industrial Service and Support segment by 2025.
“We’ve been a Xebec customer for more than a decade buying both regenerative compressed air dryers and nitrogen generators. We’re happy to now be more involved with Xebec through this acquisition and are excited to help increase the number of sales channels and provide the capability to design and manufacture full compressed air & gas systems. In addition, we’ve worked on a number of waste-to-energy projects in British Columbia and the United States such as renewable natural gas systems. We’re looking forward to being part of Xebec, a worldwide leader in renewable natural gas and hydrogen systems and see the use of renewable gases grow substantially in British Columbia over the coming years,” states Mike Sanderman, President, Applied Compression Systems Ltd.
Applied Compression Systems offers a single source solution for air & gas compression requirements. The company has a strong focus on custom designed and fabricated compressor packages for specialized applications in the oil, gas, petrochemical, alternative fuel, waste-to-energy, research, power generation, mining and manufacturing industries. ACS can supply either standard units or design and fabricate equipment that is custom-built to specific requirements from concept to completion.
“ACS is both a customer and supplier and has unique capabilities to design and build compressed air & gas systems. This acquisition will strengthen our Industrial product portfolio as a compressor integrator while simultaneously increasing our service presence in Western Canada. British Columbia is a key province for us as it’s one of two in Canada that specifically mandates supporting renewable natural gas and hydrogen. ACS’ rich experience in compressor system integration and service is well recognized and a great asset to our company.
Given their location on the west coast, it will bode positively with the strong pipeline of projects we are working on in those regions. Having local service and support will continue to be a key part in assuring customers they will be taken care of. We welcome Mike and his team to the growing portfolio of Xebec industrial companies,” says Dr. Prabhu Rao, Chief Operating Officer, Xebec Adsorption Inc.
Related links:
https://www.xebecinc.com
https://www.appliedcompression.com/
For more information:
Xebec Adsorption Inc.
Brandon Chow, Investor Relations Manager
bchow@xebecinc.com
+1 450.979.8700 ext 5762
About Xebec Adsorption Inc.
Xebec is a global provider of gas generation, purification and filtration solutions for the industrial, energy and renewables marketplace. Well-positioned in the energy transition space with proprietary technologies that transform raw gases into clean sources of renewable energy, Xebec’s 1500+ customers range from small to multi-national corporations, governments and municipalities looking to reduce their carbon footprints. Headquartered in Montréal, Quebec, Canada, Xebec has several Sales and Support offices in North America and Europe, as well as two manufacturing facilities in Montréal and Shanghai. Xebec trades on the TSX Venture Exchange under the symbol XBC. For more information, www.xebecinc.com.
Xebec Releases Inaugural Annual Sustainability Report
First report highlights progress towards meeting key industry sustainability metrics
MONTREAL, Aug. 31, 2020 (GLOBE NEWSWIRE) -- Xebec Adsorption Inc. (TSXV: XBC) (“Xebec”), a global provider of clean energy solutions is pleased to release today its inaugural 2019 ESG Report, highlighting its approach to sustainability and setting a baseline for managing and reporting on its material environmental, social, and governance (“ESG”) issues.
“Gross Domestic Product growth and prosperity should not come at the expense of environmental and social prosperity, and Xebec is committed to ensuring that it conducts business responsibly for the benefit of future generations. Xebec’s 2019 ESG Report is a first step to bring structure and process to the integration of ESG considerations in the conduct of our business that will lead to improved reporting year over year,” said Kurt Sorschak, Chairman, CEO and President of Xebec.
Reporting on Xebec’s material ESG issues is based on the standards of the Sustainability Accounting Standards Board (“SASB”) for the Industrial Machinery & Goods industry of the Resource Transformation sector, as defined by SASB’s Sustainable Industry Classification System®; these serve to determine the specific material ESG issues we report on. Xebec has also used the framework provided by the Taskforce on Climate-related Financial Disclosures (“TCFD”); these serve as a guide to the context and narrative Xebec provides for its sustainability approach in general and how the company addresses each material issue specifically.
Material issues addressed in the report:
Climate change
Energy management
Employee health and safety
Fuel economy and emissions in use-phase
Materials sourcing
Remanufacturing design and services
Xebec is implementing a continuous improvement process of managing, measuring, and reporting on those ESG issues that are critical to our business activities. With this report, we have begun the process of explicitly identifying such issues and integrating them into our governance and management processes, in order to more clearly measure and communicate how we perform on them to our stakeholders including our shareholders, employees, capital providers, governmental agencies, and the general public.
The full Xebec 2019 ESG Report can be downloaded at:
https://xebecinc.com/wp-content/uploads/2020/08/ESG-Report-2019.pdf
Related links:
https://xebecinc.com/
https://xebecinc.com/sustainability/
For more information:
Xebec Adsorption Inc.
Brandon Chow, Investor Relations Manager
bchow@xebecinc.com
+1 450.979.8700 ext 5762
About Xebec Adsorption Inc.
Xebec is a global provider of gas generation, purification and filtration solutions for the industrial, energy and renewables marketplace. Well-positioned in the energy transition space with proprietary technologies that transform raw gases into clean sources of renewable energy, Xebec’s 1500+ customers range from small to multi-national corporations, governments and municipalities looking to reduce their carbon footprints. Headquartered in Montréal, Quebec, Canada, Xebec has several Sales and Support offices in North America and Europe, as well as two manufacturing facilities in Montréal and Shanghai. Xebec trades on the TSX Venture Exchange under the symbol XBC. For more information, www.xebecinc.com.
Xebec Welcomes Ms. Sara Elford to Board of Directors
– Ms. Elford brings over 20 years of capital markets, cleantech and hydrogen experience –
MONTREAL, (QC), August 26th, 2020 – Xebec Adsorption Inc. (TSXV: XBC) (“Xebec”), a global provider of clean energy solutions is pleased to announce today that Ms. Sara Elford has joined Xebec’s Board effective August 25th, 2020.
Ms. Elford is a current board member of BioSyent Inc. and BQE Water Inc., both are TSX-V listed companies. She also served as a director of Hydrogenics Corp., a PEM fuel cell and electrolysis company, recently acquired by Cummins Inc. Ms. Elford sat on the audit and governance committees at Hydrogenics and also served on the special committee for its acquisition.
“I am very excited to bring my decades of experience in capital markets and cleantech to the Xebec team. The world is at a critical point where companies such as Xebec will play an important role in transitioning us to a sustainable and clean energy future. I’m happy to support this mission and my hope is that the insights I’ve gathered from serving on different boards over the years will be valuable to the team,” says Sara Elford.
Ms. Elford served on the board of several other formerly TSX listed companies including Carmanah Technologies (solar LED technology company taken private), TSO3 Inc. (medical device sterilization technology company acquired by Stryker Corporation), and Pure Technologies Ltd. (pipeline leak detection company acquired by Xylem Inc.).
Ms. Elford worked in capital markets for over twenty years as both an investment banking and equity research analyst. As a result, she followed an extensive range of industries and companies in the small to mid cap range and alternative energy space. Ms. Elford is a CFA Charter holder and a graduate of Bishop’s University with a Finance Major and Economics Minor. She also completed the directors’ education program with the ICD in 2015.
“I am very happy to welcome Sara to Xebec’s Board. With her insights and exposure to a wide range of industries, especially clean technologies and hydrogen, she will be able to greatly contribute to our Board work. As hydrogen will become a more important part of Xebec’s business her industry experience in this field will be extremely valuable and helpful. We’re honoured to have Sara join the Board of Xebec and the Board and I look forward working with her,” states Kurt Sorschak, Chairman, President and CEO, Xebec Adsorption Inc.
Related links:
https://www.xebecinc.com
For more information:
Xebec Adsorption Inc.
Brandon Chow, Investor Relations Manager
bchow@xebecinc.com
+1 450.979.8700 ext 5762
About Xebec Adsorption Inc.
Xebec is a global provider of gas generation, purification and filtration solutions for the industrial, energy and renewables marketplace. Well-positioned in the energy transition space with proprietary technologies that transform raw gases into clean sources of renewable energy, Xebec’s 1500+ customers range from small to multi-national corporations, governments and municipalities looking to reduce their carbon footprints. Headquartered in Montréal, Quebec, Canada, Xebec has several Sales and Support offices in North America and Europe, as well as two manufacturing facilities in Montréal and Shanghai. Xebec trades on the TSX Venture Exchange under the symbol XBC. For more information, www.xebecinc.com.
Getting closer to .05 and the R/S
Mark this post.
Its going to happen.
GLTA & JMO
File an official SEC complaint and then try a civil suit. They can run but they cant hide from the law.
GLTA & JMO
Might be the last chance to sell this above .05
I predict the end of week price will be lower than today.
GLTA & JMO
Almost ready for another Reverse Split.
I hear 4 is the charm.
LOL
GLTA & JMO
Xebec Announces Partnership with CarbonQuest to Reduce Carbon Emissions from Buildings
August 10 2020 - 08:00AM
Xebec Adsorption Inc. (TSXV: XBC) (“Xebec”), a global provider of clean energy solutions is pleased to announce it has signed an exclusive partnership agreement with CarbonQuest to reduce carbon emissions in New York City buildings. Xebec’s CO2 separation technology, specifically designed for this application, will be integrated into CarbonQuest’s Building Carbon CaptureTM system. CarbonQuest has developed a patent pending “4-Step Carbon Capture Process” which enables the separation and liquefaction of CO2 from natural gas. The captured Sustainable CO2TM will be sequestered or used in manufacturing or other industry. This partnership will bring a timely and cost-effective solution for property owners looking to meet their sustainability goals and reduce their exposure to the new Local Law 97 regulation. As a result, the partnership opens significant market opportunities for Xebec’s advanced CO2 capture technologies through CarbonQuest’s process.
In April 2019, the New York City Council passed the Climate Mobilization Act, which included a provision (Intro 1253) that limits greenhouse gas emissions from buildings over 25,000 square feet. Intro 1253 became Local Law 97 in May 2019, and now covers approximately 60,000 NYC buildings. Emissions reduction goals are 40% by 2030 and 80% by 2050, benchmarked against 2005 levels. The limits have been set in three phases for 2024-2029 (Phase 1), 2030-2034 (Phase 2) and 2035-2050 (Phase 3) and are measured in kilograms of CO2 equivalent per square foot. Any emissions above the limits will result in penalties which are set to progress in severity over time.
CarbonQuest’s initial project with Xebec is focused on the decarbonization of a multi-family property in New York City
The first Carbon Capture unit will be installed at a multifamily property in Manhattan with a well-respected property owner. The project is expected to cut 60-70% of CO2 emissions from natural gas usage. The estimated reduction in overall annual CO2 emissions will be 25% and is based on the combined carbon intensity of the building’s annual natural gas and electricity usage. The carbon capture process is expected to reduce the building’s carbon emissions such that the building is expected to be below the annual emissions limit.
“We’re excited to be collaborating with Xebec on our quest to decarbonize buildings. In urban cities, buildings are by far the number one source of carbon emissions. Our mission is simple: to enable these urban building owners to decarbonize now; thereby directly addressing the biggest source of emissions and decreasing environmental impact.
In New York City, buildings are responsible for over 70% of the city’s carbon emissions (NYC Mayor’s Office of Sustainability). New York City’s adoption of Local Law 97 is a leading example of how cities can address carbon emissions and meet their sustainability goals. Approximately 60,000 buildings will respond, resulting in what Urban Green Council estimates to be a $20 billion retrofit market for decarbonization solutions. The majority of these buildings consume natural gas and our “Building Carbon Capture” systems help building owners reduce up to 70% of their natural gas emissions before they are emitted into the atmosphere. Our initial system will remove an estimated 700 tons of C02 emissions annually and enable an overall 25% reduction in carbon emissions. This groundbreaking project will enable our first forward-thinking customer to meet the city’s sustainability goals and avoid millions of dollars of penalties over the lifecycle of the project.
We believe that Distributed Carbon Capture and UtilizationTM (DCCUTM) is a critical segment of the overall Carbon Capture and Storage ecosystem and that Building Carbon Capture is one of the most important Distributed Carbon Capture and Utilization technologies to immediately address climate change and advance urban building decarbonization. Applied at scale, we have a real opportunity to make a measurable impact in the battle against climate change,” says Shane Johnson, President and Chief Executive Officer, CarbonQuest.
“It’s a privilege for Xebec to work with CarbonQuest, a pioneer in the field, on this first of a kind project. Their carbon capture process opens a significant market opportunity for our compact and reliable equipment for CO2 separation applications.
The new regulations in NYC present a large-scale opportunity for Xebec to work with CarbonQuest to move forward our mission of decarbonizing the future. The new regulation appropriately incentivizes solutions such as ours and will help drive the implementation of new clean technologies.
Due to the unique nature of our products, we have been able to design a modular and compact unit which can be installed in the basements of these buildings. Building owners will hopefully recognize the benefits and cost savings of this novel carbon capture solution as they look to reduce their emissions instead of paying a pollution penalty,” says Dr. Prabhu Rao, Chief Operating Officer, Xebec Adsorption Inc.
Related links:
https://www.xebecinc.com
https://www.carbonquest.com
https://www1.nyc.gov/site/sustainability/codes/energy-benchmarking.page
https://www.urbangreencouncil.org/content/projects/all-about-nycs-historic-building-emissions-law
https://www.urbangreencouncil.org/sites/default/files/19.04.18_new_building_emissions_law_-_urban_green_council.pdf
https://www.urbangreencouncil.org/sites/default/files/urban_green_retrofit_market_analysis.pdf
For more information:
Xebec Adsorption Inc.
Brandon Chow, Investor Relations Manager
bchow@xebecinc.com
+1 450.979.8700 ext 5762
About CarbonQuest
CarbonQuest is leading the QUEST for decarbonization by providing urban building owners advanced technologies and solutions that ENABLE acceleration of global carbon reduction NOW. CarbonQuest is comprised of a team of seasoned environmental technology entrepreneurs focused on solving large problems. Prior to CarbonQuest, the team has collectively built several technology firms in the renewable energy, telecommunications and financial technology industries. CarbonQuest is a big believer in building strong and lasting partnerships with all stakeholders - customers, companies, employees, and cities.
$5 is on deck!
Next week we will blow by it.
GLTA & JMO
Looks strong heading into the earnings call.
See some analysts have bumped their targets into the high 5's and 6 range.
Love the way this is trading and the way management is executing.
GLTA & JMO
Wow.
Drain the swamp.. LOL
What a joke.
GLTA & JMO
Nice news and nice action today.
New 52 week high. And tomorrow may be another.
GLTA & JMO
If you cant handle normal market dynamics you should probably avoid investing.
Its nobody's job to 'hit the ask' for you.
GLTA & JMO
Disgusting.
As if that money wouldnt be better spent on existing infrastructure.
Shady AF.
What a joke in the US.
HALO is diluting to high heaven. And will be at .05 before end of year.
GLTA & JMO
I know we didnt see eye to eye on things related to MVTG/SGSI - but the meme is bang on.
GLTA & JMO
This will likely run high and hard until they get official approval. After that it will be airborn and be taken out one of the industry leading pharma companies.
Bucillamine has already been confirmed to be safe. The application for Covid related symptoms is going to be fairly obvious as it has treated similar symptoms successfully for years.
Look for a $1 or $2 price target short term.
GLTA & JMO
These are Some of the Top Companies Racing to Produce Pandemic Treatments
The global spread of the pandemic has been stunning. To date, 16.7 million people have been infected around the world. More than 660,000 people have now died. In the U.S. alone, we’ve now seen 4.3 million cases. Brazil is up to 2.4 million cases. India is up to 1.5 million cases. Russia is up to 827,455 cases. South Africa is up to nearly 460,000. Meanwhile, the World Health Organization has warned the situation could get far worse. However, the world may be nearing a vaccine, as many companies enter late-stage trial studies. So far, Moderna and Pfizer have reportedly launched two 30,000-subject trials of vaccines that could lead to regulatory approval and use later this year, according to Reuters. AstraZeneca is another one that said it will begin large scale trials in the U.S. this summer. Some of the top companies to keep an eye on include Revive Therapeutics (CSE:RVV)(OTC:RVVTF),Johnson & Johnson (NYSE:JNJ), Moderna Inc. (NASDAQ:MRNA), Eastman Kodak Company (NYSE:KODK), and Inovio Pharmaceuticals Inc. (NASDAQ:INO).
Revive Therapeutics Ltd. (CSE:RVV)(OTC:RVVTF) BREAKING NEWS: Revive Therapeutics Ltd., a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that the U.S. Food & Drug Administration has approved the Company to proceed with a randomized, double-blind, placebo-controlled confirmatory Phase 3 clinical trial protocol to evaluate the safety and efficacy of Bucillamine in patients with mild-moderate COVID-19.
“The FDA approval of the Phase 3 study to evaluate Bucillamine in the treatment of patients with mild-moderate COVID-19 is a tremendous milestone for Revive and I am very proud of the dedication of our team and partners to bring forward a potential new treatment option for patients with a confirmed diagnosis of COVID-19 globally,” said Michael Frank, Revive’s Chief Executive Officer. “We thank the FDA for recognizing the importance of this Phase 3 study and we are now focused on executing on our plans for initiating the clinical trial in an expeditious manner.”
About the Phase 3 Confirmatory Clinical Study -- The Phase 3 confirmatory clinical study titled, “A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of Bucillamine in Patients with Mild-Moderate COVID-19”, will enroll up to 1,000 patients that will be randomized 1:1:1 to receive Bucillamine 100 mg three times a day, Bucillamine 200 mg TID or placebo TID for up to 14 days. The primary objective is to compare frequency of hospitalization or death in patients with mild-moderate COVID-19 receiving Bucillamine therapy with those receiving placebo. The primary endpoint is the proportion of patients meeting a composite endpoint of hospitalization or death from the time of first dose through Day 28 following randomization. Efficacy will be assessed by comparison of clinical outcome (death or hospitalization), disease severity using the 8-category NIAID COVID ordinal scale, supplemental oxygen use, and progression of COVID-19 between patients receiving standard-of-care plus Bucillamine (high dose and/or low dose) and patients receiving standard-of-care plus placebo. Safety will be assessed by reported pre-treatment adverse events and treatment-emergent adverse events (including serious adverse events and adverse events of special interest), laboratory values (hematology and serum chemistry), vital signs (heart rate, respiratory rate, and temperature), and peripheral oxygen saturation.
An interim analysis will be performed by an Independent Data and Safety Monitoring Board after 210 patients have been treated and followed up for a total of 28 days after randomization. The better performing Bucillamine dose at the interim analysis will be selected and patients will then be randomized 2:1 to the selected Bucillamine dose or placebo. Additional interim analyses will be performed after 400, 600, and 800 patients have reached this same post-treatment timepoint. The independent DSMB will actively monitor interim data for the ongoing safety of patients and will recommend continuation, stopping or changes to the conduct of the study based on the interim analysis reports.
Scientific Rationale of Bucillamine for COVID-19 -- Preclinical and clinical studies have demonstrated that reactive oxygen species contribute to the destruction and programmed cell death of pulmonary epithelial cells. N-acetyl-cysteine (NAC) has been shown to significantly attenuate clinical symptoms in respiratory viral infections in animals and humans, primarily via donation of thiols to increase antioxidant activity of cellular glutathione. Bucillamine (N-(mercapto-2-methylpropionyl)-l-cysteine) has a well-known safety profile and is prescribed in the treatment of rheumatoid arthritis in Japan and South Korea for over 30 years. Bucillamine, a cysteine derivative with two thiol groups, has been shown to be 16 times more potent as a thiol donor in vivo than NAC 6. The drug is non-toxic with high cellular permeability. The basis of the clinical study will analyze if Bucillamine has the potential, via increasing glutathione activity and other anti-inflammatory activity, to lessen the destructive consequences of SARS-CoV2 infection in the lungs and attenuate the clinical course of COVID-19.
The Company is not making any express or implied claims that its product has the ability to eliminate or cure COVID-19 (SARS-2 Coronavirus) at this time.
Other related developments from around the markets include:
Johnson & Johnson (NYSE:JNJ) announced that its lead vaccine candidate protected against infection with SARS-CoV-2, the virus that causes COVID-19, in pre-clinical studies. The data, published in Nature, show the Company’s investigational adenovirus serotype 26 (Ad26) vector-based vaccine elicited a robust immune response as demonstrated by “neutralizing antibodies,” successfully preventing subsequent infection and providing complete or near-complete protection in the lungs from the virus in non-human primates (NHPs) in the pre-clinical study. Based on the strength of the data, a Phase 1/2a first-in-human clinical trial of the vaccine candidate, Ad26.COV2.S, in healthy volunteers, has now commenced in the United States and Belgium. “We are excited to see these pre-clinical data because they show our SARS-CoV-2 vaccine candidate generated a strong antibody response and provided protection with a single dose. The findings give us confidence as we progress our vaccine development and upscale manufacturing in parallel, having initiated a Phase 1/2a trial in July with the intention to move into a Phase 3 trial in September,” said Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific Officer, Johnson & Johnson.
Moderna Inc. (NASDAQ:MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, announced a preclinical study evaluating mRNA-1273, its vaccine candidate against COVID-19, was published in The New England Journal of Medicine. The study showed a two-dose vaccination schedule of mRNA-1273 led to a robust immune response and protection against SARS-CoV-2 infection in the upper and lower airways in non-human primates, without evidence of vaccine-associated enhanced respiratory disease (VAERD). In the study, immunogenicity and protective efficacy were assessed after a two-dose vaccination schedule of 10 or 100 µg doses of mRNA-1273 or control given four weeks apart (n=24; 8 per group). Four weeks after the second vaccination, animals were challenged with high doses of SARS-CoV-2 through intranasal and intratracheal routes.
Eastman Kodak Company (NYSE:KODK) recently received a $765 million loan to support the launch of Kodak Pharmaceuticals from the White House. “With this new agreement, my administration is using the Defense Production Act to provide a $765 million loan to support the launch of Kodak Pharmaceuticals,” said President Trump. “Kodak will now produce generic active pharmaceutical ingredients, which is a big deal. Using advanced manufacturing techniques, Kodak will also make the key starting materials that are the building blocks for many drugs in a manner that is both cost-competitive and environmentally safe. We’ll be competitive with almost all countries, and soon with all countries.”
Inovio Pharmaceuticals Inc. (NASDAQ:INO) a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today announced that its COVID-19 DNA vaccine INO-4800 targeting SARS-CoV-2 was effective in protecting non-human primates (NHPs; specifically rhesus macaques) from live virus challenge 13 weeks after the last vaccination. These protective results were mediated by memory T and B cell immune responses from INO-4800 vaccination. These results, submitted to a peer-reviewed journal and also published today on the non-peer reviewed online preprint site bioRxiv, demonstrate that INO-4800 reduced viral load in both the lower lungs and nasal passages in macaques that received two doses of INO-4800 (1 mg) four weeks apart and then were challenged with live virus 13 weeks after the second dose (study week 17). The reduced viral loads following exposure to SARS-CoV-2 infection at this timeframe demonstrate an important durable impact mediated by INO-4800. This is the first time a vaccine protection in non-human primates was reported from memory immune responses as previously reported monkey vaccine challenge studies were conducted at the time near their peak immune responses (1-4 weeks from their last vaccination). INO-4800-treated animals demonstrated seroconversion after a single vaccination, with protective neutralizing antibodies and T cells lasting in their blood more than four months after the initial dose. The antibody levels were similar to or greater than those seen in patients who have recovered from COVID-19, the infection caused by SARS-CoV-2, and the T cell responses were significantly higher than those from convalescent patients.
Legal Disclaimer / Except for the historical information presented herein, matters discussed in this article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Winning Media is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. For making specific investment decisions, readers should seek their own advice. Revive Therapeutics has paid three thousand five hundred dollars for advertising and marketing services to be distributed by Winning Media. Winning Media is only compensated for its services in the form of cash-based compensation. Winning Media owns ZERO shares of Revive Therapeutics. Please click here for full disclaimer.
Contact Information:
2818047972
ty@wallstreetnation.com
Livemoney US Market Commentary
July 31, 2020 - 9:07 AM PDT
Nice day heading into the weekend.
Next week should be ship shape and priming for a great Q hopefully!
GLTA & JMO
She's winding up for another run!
GLTA & JMO
Xebec Receives $6.3M in Purification Orders as Adoption for Hydrogen Accelerates Worldwide
Xebec’s PSA platform enables more cost effective and greener hydrogen for industry and transportation
MONTREAL, July 27, 2020 (GLOBE NEWSWIRE) -- Xebec Adsorption Inc. (TSXV: XBC) (“Xebec”), a global provider of clean energy solutions is pleased to announce that it has received $6.3 million in hydrogen and helium PSA purification orders from customers in South Korea, United States, Canada, Italy, Poland, Trinidad and Tobago, and China. As worldwide adoption for hydrogen accelerates, Xebec’s robust and efficient PSA technology is being selected for integration into steam methane reforming and electrolysis hydrogen generation systems. The PSA platform ensures hydrogen production can cost effectively and efficiently meet the industry standard of 99.999% purity for use in fuel cell vehicles (“FCV”) and industry.
“When BayoTech was looking for a proven PSA technology to complete our hydrogen generators, Xebec was a great solution. There are few companies in the world that can offer a product which could fit with our containerized systems and achieve the high purity hydrogen required for fuel cell vehicles. We were impressed with Xebec’s long track record, innovative products and capabilities. We see them as a strong partner and look forward to growing together,” states Dwayne Victor, Director, Global Sourcing, BayoTech.
Governments around the world are supporting the increased use of hydrogen
On June 25th, 2020, the California Air Resources Board adopted a “first-in-the-world” rule requiring truck manufacturers to transition from diesel trucks and vans to zero-emission vehicles (battery electric and fuel cell electric), with a plan for every new truck sold in California to be zero-emission by 2045. This ruling will help California meet its climate goals and federal air quality standards.
The European Commission announced on July 7th, 2020 their hydrogen strategy to achieve a climate neutral Europe. The strategy has several phases, the first one includes the installation of at least 6GW of renewable hydrogen electrolyzers in the EU by 2024 and production of up to one million tons of renewable hydrogen. There is approximately 1GW of electrolyzers installed in the EU today. The second phase (2024-30) includes the installation of at least 40GW of electrolyzers by 2030 and the production of up to ten million tons of renewable hydrogen. Furthermore, there are several financial instruments to support hydrogen development and investment such as the €560 billion Next Generation EU facility, the European Regional Development Fund and the Cohesion Fund, and the €10 billion ETS Innovation Fund.
South Korea outlined a plan on July 14th, 2020 to spend 114.1 trillion won ($128 billion CAD) to create jobs and help the economy recover from the coronavirus pandemic. This includes in part, further investment into electric and hydrogen fuel cell vehicles to help achieve net-zero emissions by 2050. The country aims to have 1.13 million electric vehicles (EVs) and 200,000 hydrogen cars on the roads by 2025, up from 91,000 and 5,000 each by the end of 2019.
In April of this year, China’s National Energy Administration issued a draft Development Plan for the New Energy Vehicle Industry 2021-2035 that included hydrogen as an energy source for the first time. Its focus is on the development of hydrogen vehicle technology and the roll out of hydrogen refueling infrastructure and storage. In addition, Beijing mapped out a plan in 2019 to increase the number of hydrogen filling stations to 1,000 and have one million FCVs on the road by 2030.
“Xebec is in a unique position with our PSA platform because it can be used in all hydrogen generation systems. Hydrogen comes out of a steam methane reformer or electrolyzer with impurities that need to be removed in order to achieve a desired quality. We’ve been developing our purification technology for decades and it is a tried and tested solution that can be applied to everything from helium, renewable natural gas, and hydrogen. It’s exciting to see our Cleantech systems order flow pick up as we continue to grapple with the need to decarbonize and fight climate change,” says Dr. Prabhu Rao, Chief Operating Officer, Xebec Adsorption Inc.
Related links:
https://www.xebecinc.com
https://ww2.arb.ca.gov/news/california-takes-bold-step-reduce-truck-pollution
https://www.reuters.com/article/us-southkorea-president-newdeal-idUSKCN24F0GA
https://ec.europa.eu/commission/presscorner/detail/en/qanda_20_1257
https://asia.nikkei.com/Business/China-tech/Hydrogen-Valley-powers-China-s-fuel-cell-industry
For more information:
Xebec Adsorption Inc.
Brandon Chow, Investor Relations Manager
bchow@xebecinc.com
+1 450.979.8700 ext 5762
About Xebec Adsorption Inc.
Xebec is a global provider of gas generation, purification and filtration solutions for the industrial, energy and renewables marketplace. Well-positioned in the energy transition space with proprietary technologies that transform raw gases into clean sources of renewable energy, Xebec’s 1500+ customers range from small to multi-national corporations, governments and municipalities looking to reduce their carbon footprints. Headquartered in Montréal, Quebec, Canada, Xebec has several Sales and Support offices in North America and Europe, as well as two manufacturing facilities in Montréal and Shanghai. Xebec trades on the TSX Venture Exchange under the symbol XBC. For more information, www.xebecinc.com.
About BayoTech Inc.
BayoTech is an energy solutions company committed to addressing the need for consistent, cost-effective supply of hydrogen. We offer modular, scalable, and rapidly deployable hydrogen generation plants for on-site hydrogen production that empower our customers to take control of their hydrogen supply chain. BayoTech’s steam methane reformers achieve high energy efficiency without dependence on exported steam by high recuperation of heat for internal use. Further, the BayoTech reformer has a small form factor, allowing it to be deployed at or near the point of use. This significant improvement in efficiency, along with eliminating transportation need, translates into a reduced carbon footprint.
Trip zeros are not that far away.. for the 12th time.
Lets see if SGSI/MVTG/LOL can set a record for number of reverse splits.
GLTA & JMO